聚丁基腈基丙烯酸酯(PBCA)毫微粒混悬剂,一般以冻干的方式来保持其稳定性。但当需要静脉给药时,由于这些冻干的毫微粒重新混悬时,微粒有凝集的危险,重新混悬不充分易引起微栓塞。因此通常需要强大的超声浴来确保充分重新混悬,并需要测定微粒的大小。这就严重限制了它的临床应用 Polybutyl cyanoacrylate (PBCA) nanoparticulate suspensions, which generally maintain their stability in a lyophilized fashion. However, when intravenous administration is required, micro-embolization can be easily caused by inadequate resuspension due to the risk of agglutination of the lyophilized nanoparticles when resuspended. Therefore, a powerful sonication bath is often required to ensure adequate resuspension and to determine the size of the particles. This severely limits its clinical application